- Report
- December 2021
Global
From €4700EUR$4,850USD£4,026GBP
- Report
- February 2020
- 200 Pages
Japan, United States, ... Japan, United States, Europe, Global
From €4361EUR$4,500USD£3,735GBP
From €533EUR$550USD£457GBP
- Report
- August 2023
Japan, United States, ... Japan, United States, Europe
From €1454EUR$1,500USD£1,245GBP
- Report
- April 2022
Japan, United States, ... Japan, United States, Europe, Global
From €2665EUR$2,750USD£2,283GBP
The Aeromonads Test market is a subset of the Infectious Disease Testing market. It is focused on the detection of Aeromonas species, a group of Gram-negative bacteria that can cause a range of diseases in humans. Aeromonads Tests are used to diagnose infections, monitor treatment, and detect the presence of antibiotic-resistant strains. Tests are available in a variety of formats, including culture, PCR, and ELISA.
The Aeromonads Test market is driven by the increasing prevalence of Aeromonas infections, as well as the need for rapid and accurate diagnosis. The market is expected to grow in the coming years, as new technologies and improved diagnostics become available.
Some companies in the Aeromonads Test market include Bio-Rad Laboratories, Thermo Fisher Scientific, Becton Dickinson, and Roche Diagnostics. Show Less Read more
